Product logins

Find logins to all Clarivate products below.


Pemphigus Vulgaris – Epidemiology – Epidemiology Dashboard

Clarivate Epidemiology’s coverage of pemphigus vulgaris comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the diagnosed prevalence and the diagnosed incidence of pemphigus vulgaris for each country, as well as annualized case counts projected to the national population.

Most patient populations are forecast over a period of 20 years for the mature markets and Europe and 10 years for the other countries we cover.

All forecast data are available on Clarivate’s Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.

Clarivate Epidemiology’s pemphigus vulgaris forecast answers the following questions:

  • How will changes in the levels of exposure to known risk or protective factors affect the number of people living with a diagnosis of pemphigus vulgaris and the number of new diagnoses of pemphigus vulgaris?
  • In developing countries, what impact will economic growth and development have on the number of people living with a diagnosis of pemphigus vulgaris and the number of new diagnoses of pemphigus vulgaris?
  • How will improvements in survival change the number of people living with a diagnosis of pemphigus vulgaris?
  • How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of pemphigus vulgaris over the forecast period?

In addition to the total number of cases for each forecast year, Clarivate Epidemiology provides at least 10 years of forecast data for the following pemphigus vulgaris subpopulations:

  • Diagnosed incident cases
  • Diagnosed prevalent cases
  • Diagnosed incident cases by severity

Note: Coverage may vary by country.

Related Market Assessment Reports

Report
Biosimilars – Access & Reimbursement – Payer Insights Landscape (US/EU)
Biosimilar regulations and guidance have been defined, at least in draft form, in most the world’s leading pharmaceutical markets. In many cases, biosimilar guidance is based on that of the EMA,…
Report
Ovarian Cancer – Landscape & Forecast – Disease Landscape & Forecast (G7)
The treatment landscape for ovarian cancer has been revolutionized by the angiogenesis inhibitor bevacizumab and the PARP inhibitors olaparib (Lynparza; AstraZeneca / Merck & Co.), niraparib (…
Report
Myelodysplastic Syndromes – Landscape & Forecast – Niche & Rare Disease Landscape & Forecast
Myelodysplastic syndromes (MDS) are a heterogeneous group of hematopoietic stem cell disorders that result in cytopenia with the risk of progression to acute myeloid leukemia (AML). The FDA’s and…
Report
Vitiligo – Current Treatment – Treatment Algorithms: Claims Data Analysis – Vitiligo (US)
Vitiligo is a chronic skin depigmentation disorder characterized by the destruction or functional loss of melanocytes. Given its visible manifestations, the disease is associated with a substantial…
Report
Ulcerative Colitis – Unmet Need – Unmet Need – Moderate to Severe Ulcerative Colitis (US/EU)
The treatment landscape for ulcerative colitis (UC) is rapidly evolving. TNF-alpha inhibitors (Johnson & Johnson Innovative Medicine’s Remicade, AbbVie’s Humira), a CAM inhibitor (Takeda’s…